Brought to you by 
Adaptive Bio goes public netting $321mm
02 Jul 2019
Executive Summary
Adaptive Biotechnologies Corp. (immunosequencing diagnostics) netted $320.85mm in its oversubscribed initial public offering of 17.25mm common shares (including full exercise of the overallotment) at $20 each on the Nasdaq. The company planned to sell 12.5mm shares between $15 and $17 each.
Deal Industry
- Research, Analytical Equipment & Supplies
- Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
Pharmaceuticals
- Vaccines
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Gene Therapy, Cell Therapy
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adaptive Bio goes public netting $321mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice